Updates are available Correction dated 2023-03-20
Click to view Correction: https://doi.org/10.1038/s43587-023-00396-z
-
Authors
Fang, Jiansong
Zhang, Pengyue
Zhou, Yadi
Chiang, Chien-Wei
Tan, Juan
Hou, Yuan
Stauffer, Shaun
Li, Lang
Pieper, Andrew A.
Cummings, Jeffrey
Cheng, Feixiong http://orcid.org/0000-0002-1736-2847
-
Funding
Funding for this research was provided by:
Foundation for the National Institutes of Health (P30AG072959, 1P30 AGO62428-01, P20GM109025, U01NS093334, R01AG053798, 1R35AG71476-01, 3 R01 AG066707-02S1, R01AG066707, U01AG073323, 3R01AG066707-01S1, 1R56AG074001-01)
- License Information
-
More Information
Article History
Received: 28 August 2020
Accepted: 15 October 2021
First Online: 6 December 2021
Change Date: 20 March 2023
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1038/s43587-023-00396-z
Competing interests
: J.C. has provided consultation to Acadia, Actinogen, Alkahest, Alzheon, Annovis, Avanir, Axsome, Biogen, BioXcel, Cassava, Cerecin, Cerevel, Cortexyme, Cytox, EIP Pharma, Eisai, Foresight, GemVax, Genentech, Green Valley, Grifols, Karuna, Merck, Novo Nordisk, Otsuka, Resverlogix, Roche, Samumed, Samus, Signant Health, Suven, Third Rock and United Neuroscience pharmaceutical and assessment companies. J.C. has stock options in ADAMAS, AnnovisBio, MedAvante and BiOasis. The other authors declare no competing interests.
